LQB183 Assessment Item 2 Annotated BibliographyWritten by Joseph SmithResearch QuestionIs Infleximab effective in treating the symptoms of Crohn's disease?Task Words: Annotated Bibliography; effective in the treatment Thematic words: symptoms Limiting words: Infleximab, Crohn's disease1 Brief articleSeung Lee, J. et al. (2010) Effectiveness of early treatment with infliximab in pediatric Crohn's disease. World Journal of Gastroenterology, 1776-1781 DOI: 10.3748/wjg.v16.i14.1776 Throughout this brief article, Seung Lee et al. looks at the effectiveness of early use of infliximab with maintenance and induction therapy in Crohn's disease. The study mainly aims to improve Infliximab, which is achieved through numerous control measures contrasting its effects with melamine, azathiorpine and prednisolone. A small group of patients was subdivided into 3 groups A, B and C and were subjected to oral ingestion of the previously indicated drugs. By monitoring the activity index over an observation period of 12 and 24 months, the relapse rate would ultimately determine the effectiveness of the drug. Seung Lee et al. provides general statistics that highlight the usefulness of this article by showing the connections between medications and their strengths and weaknesses based on age, time period, and health-related considerations. Although the study showed promising results, the article states that more experiments cannot be absolutely conclusive because there was selection bias with a very small test group. The “top-down” approach used by the study is also not considered a widely accepted method among healthcare professionals since it is still a new practice. Additionally, the experience is also limited by a duration of 2 years...... middle of paper...... A minimum of 3 induction doses was required. Patients who experienced a decreased response to infliximab were subjected to a dose increase (5 mg/kg to 10 mg/kg). Any signs of worsening symptoms or related inflammation would lead to this procedure. A limitation is that the report indicates that the statistical data could be improved if the sample size had been more varied in terms of patients' medical histories and the number of patients observed. Chaparro suggests that increasing the dose of infliximab is a safe and effective measure, but that the effects are only short-term and that patients' response disappears after 12 months of follow-up. This article can be used to demonstrate greater understanding and insight into how the medication is used. This article would be useful as it directly relates to the effectiveness of infliximabs and helps expand on the topic..